These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16699254)

  • 1. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
    Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
    Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M; Kodric M; Longo C; Vassallo FG
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan for patients with chronic thromboembolic pulmonary hypertension.
    Vassallo FG; Kodric M; Scarduelli C; Harari S; Potena A; Scarda A; Piattella M; Cassandro R; Confalonieri M
    Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
    Hughes RJ; Jais X; Bonderman D; Suntharalingam J; Humbert M; Lang I; Simonneau G; Pepke-Zaba J
    Eur Respir J; 2006 Jul; 28(1):138-43. PubMed ID: 16611652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
    Surie S; Reesink HJ; Marcus JT; van der Plas MN; Kloek JJ; Vonk-Noordegraaf A; Bresser P
    Clin Cardiol; 2013 Nov; 36(11):698-703. PubMed ID: 24037998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
    Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC
    Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
    Baptista R; Castro G; da Silva AM; Monteiro P; Providência LA
    Rev Port Cardiol; 2013 Feb; 32(2):123-9. PubMed ID: 23351920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
    Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
    Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
    Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
    Bonderman D; Nowotny R; Skoro-Sajer N; Jakowitsch J; Adlbrecht C; Klepetko W; Lang IM
    Chest; 2005 Oct; 128(4):2599-603. PubMed ID: 16236930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    Monfredi O; Griffiths L; Clarke B; Mahadevan VS
    Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.